Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial.
A B GottliebA KubanovM van DoornJ SullivanKim A PappR YouP RegnaultJ A FruehPublished in: The British journal of dermatology (2019)
GESTURE revealed that secukinumab provides a strong and sustained response over 2·5 years in challenging-to-treat palmoplantar psoriasis.